- Home
- NCMI vs SIGA Comparison
NCMI vs SIGA Comparison
Compare NCMI & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCMI | SIGA |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 341.0M |
| IPO Year | 2006 | 2016 |
Fundamental Metrics
Financial Performance| Metric | NCMI | SIGA |
|---|---|---|
| Price | $3.00 | $4.72 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.63 | N/A |
| AVG Volume (30 Days) | 258.0K | ★ 486.6K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | 3.36% | ★ 13.24% |
| EPS Growth | ★ 52.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.20 | N/A |
| Revenue Next Year | $6.22 | $224.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.80 | $4.10 |
| 52 Week High | $5.56 | $9.62 |
Technical Indicators
Market Signals| Indicator | NCMI | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 37.02 | 54.61 |
| Support Level | $2.86 | $4.19 |
| Resistance Level | $3.76 | $4.86 |
| Average True Range (ATR) | 0.15 | 0.21 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 21.16 | 75.15 |
Price Performance
Historical ComparisonAbout NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.